Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-Grade Urothelial Carcinoma with Divergent Prostatic Differentiation Mimicking a Collision Tumor in a Bladder Diverticulum.

International journal of surgical pathology·2026
Same author

Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma.

Leukemia·2026
Same author

Intratumoral preservation of the stem-like malignant cell proportion in glioblastoma, prognostic impact, and its radiomethylomic signatures.

Neuro-oncology·2025
Same author

Leukemia mutated proteins PHF6 and PHIP form a chromatin complex that represses acute myeloid leukemia stemness.

Genes & development·2025
Same author

ATM-dependent DNA damage response constrains cell growth and drives clonal hematopoiesis in telomere biology disorders.

The Journal of clinical investigation·2025
Same author

The FBXO45-GEF-H1 Axis Controls Germinal Center Formation and B-cell Lymphomagenesis.

Cancer discovery·2025
Same journal

Analysis of strength degradation of coal and rock masses and stability of mined areas under long term immersion environment.

PloS one·2026
Same journal

Biogenic Silver-Selenium nanocomposite with anticancer activity and potent efficacy against vancomycin-resistant Staphylococcus aureus.

PloS one·2026
Same journal

Preparation and physicochemical characterization of a biodegradable chitosan/carboxymethyl cellulose hydrogel synthesized in NaOH/urea medium.

PloS one·2026
Same journal

Action-guilt, survivor-guilt, and depression in combat-related PTSD.

PloS one·2026
Same journal

Explainable machine learning for predicting activities of daily living at discharge in stroke patients: A retrospective study using SHAP interpretability.

PloS one·2026
Same journal

Deep learning based two-way feature depiction model for brain tumor detection.

PloS one·2026
See all related articles

Related Experiment Video

Updated: Mar 23, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.4K

Building a Robust Tumor Profiling Program: Synergy between Next-Generation Sequencing and Targeted Single-Gene

Matthew C Hiemenz1, Stephan Kadauke2, David B Lieberman1

  • 1Center for Personalized Diagnostics, Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.

Plos One
|April 5, 2016
PubMed
Summary
This summary is machine-generated.

Next-generation sequencing (NGS) reliably detects cancer mutations. Implementing quality control metrics ensures accurate NGS results for clinical oncology, facilitating broader adoption.

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K
Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing
11:02

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing

Published on: October 18, 2013

20.0K

Related Experiment Videos

Last Updated: Mar 23, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.4K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K
Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing
11:02

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing

Published on: October 18, 2013

20.0K

Area of Science:

  • Oncology
  • Genomics
  • Molecular Diagnostics

Background:

  • Next-generation sequencing (NGS) is crucial for identifying cancer mutations.
  • Clinical implementation of NGS necessitates robust quality control (QC) metrics for accuracy.
  • Evaluating NGS pipeline performance is vital for routine clinical use.

Purpose of the Study:

  • To assess the robustness and reliability of a clinical NGS pipeline.
  • To compare NGS results with targeted single-gene tests in solid tumors and hematologic malignancies.
  • To validate the effectiveness of QC metrics in ensuring accurate NGS detection of cancer mutations.

Main Methods:

  • Analysis of 304 solid tumor and hematologic malignancy specimens.
  • Simultaneous testing using NGS and targeted single-gene assays (EGFR, KRAS, BRAF, NPM1, FLT3, JAK2).
  • Evaluation of concordance and identification of clinically significant mutations, considering validated tumor percentage and DNA quality thresholds.

Main Results:

  • Perfect concordance between NGS and targeted tests for samples meeting QC thresholds.
  • Two FLT3 internal tandem duplications detected by NGS but below the initial reporting limit.
  • NGS identified additional clinically relevant mutations beyond single-gene panels.
  • The study confirmed NGS reliability with appropriate QC measures.

Conclusions:

  • NGS is a dependable platform for clinical cancer mutation identification.
  • Implementing stringent QC metrics, including tumor percentage and DNA quality, is essential for accurate NGS results.
  • The proposed workflow can aid other institutions in adopting clinical oncologic NGS services.